Clinical Trial

Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer

Study acronym: Regynera-RT
Recruiting
View on ClinicalTrials.gov →
Summary
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
Trial Details
NCT Number NCT07667192
Lead Sponsor Affidea Nu-med Center of Oncological DIagnostics and Therapy
Conditions Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 500 participants
Start Date 2026-06-11
Primary Completion 2031-12 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-24